SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EARNINGS FLASH L impact

Latigo Biotherapeutics Reports Third-Quarter 2026 EPS of ($0.55)

The company’s net loss narrowed year over year as lower research and development spending more than offset higher general and administrative expenses. Other income also improved.

LTGO

Related stories